Low survival due to higher risk of relapse and non-relapse mortality after allogeneic HSCT in ATL compared with AML and ALL.
Tomori S, Morishima S, Kato K, Nakasone H, Nakano N, Eto T, Kawakita T, Suehiro Y, Miyazaki Y, Uchida N, Sawayama Y, Mori Y, Nakamae H, Nagafuji K, Uehara Y, Doki N, Kanda J, Fukuda T, Atsuta Y, Yoshimitsu M; JSTCT ATL Working Group and JSTCT Transplant Complications Working Group.
Tomori S, et al. Among authors: miyazaki y.
Transplant Cell Ther. 2025 Jan 17:S2666-6367(25)00909-1. doi: 10.1016/j.jtct.2025.01.882. Online ahead of print.
Transplant Cell Ther. 2025.
PMID: 39828057